Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADUS NASDAQ:CELC NYSE:HIMS NYSE:PACS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADUSAddus HomeCare$99.46+2.2%$97.85$90.89▼$124.43$1.86B0.92241,845 shs34,823 shsCELCCelcuity$131.94+0.9%$116.46$9.51▼$151.02$6.38B0.09800,433 shs106,820 shsHIMSHims & Hers Health$26.40+2.9%$22.56$13.74▼$70.43$6.04B2.4332.65 million shs5.47 million shsPACSPACS Group$33.50-0.4%$34.37$7.50▼$43.08$5.27B-0.03904,155 shs94,646 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADUSAddus HomeCare+0.67%+0.41%+4.44%-8.11%-13.33%CELCCelcuity-6.26%+7.71%+13.11%+22.44%+1,182.85%HIMSHims & Hers Health-4.78%-5.85%+31.43%+11.54%-50.69%PACSPACS Group-0.56%+0.06%+3.80%-12.82%+219.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADUSAddus HomeCare$99.46+2.2%$97.85$90.89▼$124.43$1.86B0.92241,845 shs34,823 shsCELCCelcuity$131.94+0.9%$116.46$9.51▼$151.02$6.38B0.09800,433 shs106,820 shsHIMSHims & Hers Health$26.40+2.9%$22.56$13.74▼$70.43$6.04B2.4332.65 million shs5.47 million shsPACSPACS Group$33.50-0.4%$34.37$7.50▼$43.08$5.27B-0.03904,155 shs94,646 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADUSAddus HomeCare+0.67%+0.41%+4.44%-8.11%-13.33%CELCCelcuity-6.26%+7.71%+13.11%+22.44%+1,182.85%HIMSHims & Hers Health-4.78%-5.85%+31.43%+11.54%-50.69%PACSPACS Group-0.56%+0.06%+3.80%-12.82%+219.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADUSAddus HomeCare 2.73Moderate Buy$132.3333.06% UpsideCELCCelcuity 2.75Moderate Buy$134.501.94% UpsideHIMSHims & Hers Health 2.18Hold$31.8620.67% UpsidePACSPACS Group 3.00Buy$44.4032.55% UpsideCurrent Analyst Ratings BreakdownLatest ADUS, CELC, HIMS, and PACS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026ADUSAddus HomeCare Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$150.00 ➝ $142.005/5/2026HIMSHims & Hers Health Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$25.005/4/2026CELCCelcuity Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$189.005/4/2026CELCCelcuity GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$135.00 ➝ $165.005/4/2026CELCCelcuity Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$150.005/4/2026CELCCelcuity CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/4/2026CELCCelcuity Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$150.00 ➝ $160.005/4/2026CELCCelcuity Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$122.00 ➝ $157.004/27/2026CELCCelcuity CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform4/27/2026CELCCelcuity Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$150.004/24/2026HIMSHims & Hers Health JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$35.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADUSAddus HomeCare$1.45B1.28$6.68 per share14.88$59.80 per share1.66CELCCelcuityN/AN/AN/AN/A$2.17 per shareN/AHIMSHims & Hers Health$2.35B2.56$0.82 per share32.12$2.38 per share11.09PACSPACS Group$5.29B1.00$1.58 per share21.16$6.08 per share5.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADUSAddus HomeCare$95.91M$5.4118.3814.821.336.89%9.80%7.34%N/ACELCCelcuity-$177.04M-$3.79N/A2,199.03N/AN/A-203.17%-52.68%5/13/2026 (Estimated)HIMSHims & Hers Health$128.37M$0.5151.9939.403.675.47%22.48%7.02%5/11/2026 (Confirmed)PACSPACS Group$191.54M$1.2327.2513.731.033.62%22.55%3.45%5/11/2026 (Confirmed)Latest ADUS, CELC, HIMS, and PACS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026CELCCelcuity-$1.07N/AN/AN/A$2.94 millionN/A5/11/2026Q1 2026HIMSHims & Hers Health$0.04N/AN/AN/A$616.88 millionN/A5/11/2026Q1 2026PACSPACS Group$0.42N/AN/AN/A$1.36 billionN/A5/4/2026Q1 2026ADUSAddus HomeCare$1.52$1.62+$0.10$1.36$366.41 million$363.50 million3/25/2026Q4 2025CELCCelcuity-$1.06-$0.97+$0.09-$0.97$1.28 millionN/A2/23/2026Q4 2025HIMSHims & Hers Health$0.02$0.08+$0.06$0.08$619.48 million$617.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADUSAddus HomeCareN/AN/AN/AN/AN/ACELCCelcuityN/AN/AN/AN/AN/AHIMSHims & Hers HealthN/AN/AN/AN/AN/APACSPACS GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADUSAddus HomeCare0.081.831.80CELCCelcuity3.2010.5510.55HIMSHims & Hers Health1.801.901.70PACSPACS Group0.361.071.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADUSAddus HomeCare95.35%CELCCelcuity63.33%HIMSHims & Hers Health63.52%PACSPACS GroupN/AInsider OwnershipCompanyInsider OwnershipADUSAddus HomeCare4.50%CELCCelcuity13.33%HIMSHims & Hers Health13.71%PACSPACS Group70.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADUSAddus HomeCare50,65918.67 million17.83 millionOptionableCELCCelcuity4048.34 million41.89 millionOptionableHIMSHims & Hers Health2,442227.94 million196.69 millionOptionablePACSPACS Group47,455157.16 million46.52 millionOptionableADUS, CELC, HIMS, and PACS HeadlinesRecent News About These CompaniesPACS Group (PACS) Expected to Announce Earnings on ThursdayMay 6 at 4:03 AM | americanbankingnews.comPACS Group Intends to Release First Quarter 2026 Earnings on Monday, May 11, 2026, and Host a Call to Discuss Financial Results on Tuesday, May 12, 2026May 5 at 6:00 AM | businesswire.comA new class of super PACs is emerging. Voters are wary.May 5 at 1:03 AM | politico.comPPACS Group (NYSE:PACS) Downgraded to Hold Rating by Wall Street ZenMay 2, 2026 | americanbankingnews.comPACS Group (NYSE:PACS) Rating Lowered to Hold at Wall Street ZenMay 2, 2026 | marketbeat.comSkilled Nursing Dealbook: Ensign Acquires 17 Texas Facilities; PACS Expands in Alaska With Plans to Build 150-Bed FacilityMay 1, 2026 | skillednursingnews.comSPACS Group Announces Acquisition in Alaska; New Construction of a Skilled Nursing CommunityMay 1, 2026 | businesswire.comPACS Group (PACS) Appoints Carey P. Hendrickson as Chief Financial OfficerMay 1, 2026 | finance.yahoo.comPACS Group (PACS) Expected to Announce Quarterly Earnings on ThursdayApril 30, 2026 | marketbeat.comPACS Group (NYSE:PACS) Shares Gap Down - Time to Sell?April 29, 2026 | marketbeat.comIs It Too Late To Consider PACS Group (PACS) After Its 266.3% One-Year Surge?April 28, 2026 | finance.yahoo.comUniversal Beteiligungs und Servicegesellschaft mbH Has $7.45 Million Stake in PACS Group, Inc. $PACSApril 28, 2026 | marketbeat.com‘It’s in our DNA’: Nursing Home Giant PACS CEO on Compliance Transformation After Investigation, Growth, $100M Tech InvestmentsApril 27, 2026 | skillednursingnews.comSPACS Group Says Carey Hendrickson to Succeed Co-Founder Mark Hancock as CFOApril 27, 2026 | marketwatch.comPACS Group, Inc. Announces the Appointment of Carey P. Hendrickson as Chief Financial OfficerApril 27, 2026 | businesswire.comPACS Group, Inc. Announces Retirement of Co-Founder and CFO Mark HancockApril 27, 2026 | businesswire.comWall Street Analysts Think PACS Group, Inc. (PACS) Could Surge 30.96%: Read This Before Placing a BetApril 27, 2026 | zacks.comPACS or MEDP: Which Is the Better Value Stock Right Now?April 24, 2026 | zacks.comConservative group claims PAC misused name in Sullivan County mayoral adsApril 22, 2026 | msn.comPACS SHAREHOLDER ALERT: Kaskela Law Firm Announces Investigation of PACS Group, Inc.(PACS) and Encourages Long-Term PACS Investors with Losses to Contact the FirmApril 21, 2026 | globenewswire.comPACS Group, Inc. (NYSE:PACS) Given Consensus Rating of "Buy" by AnalystsApril 21, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 20263 Healthcare Stocks Providing Relief for the Sandwich GenerationBy Chris Markoch | April 10, 2026What the FDA's Latest Proposal Means for Lilly, Novo, and HimsBy Leo Miller | May 7, 2026Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance MeansBy Leo Miller | April 28, 2026ADUS, CELC, HIMS, and PACS Company DescriptionsAddus HomeCare NASDAQ:ADUS$99.46 +2.17 (+2.23%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.Celcuity NASDAQ:CELC$131.94 +1.23 (+0.94%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.Hims & Hers Health NYSE:HIMS$26.40 +0.75 (+2.92%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.PACS Group NYSE:PACS$33.50 -0.13 (-0.40%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
